These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25574921)

  • 1. Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients.
    Mah A; Kharrat H; Ahmed R; Gao Z; Der E; Hansen E; Long R; Kunimoto D; Cooper R
    Int J Tuberc Lung Dis; 2015 Feb; 19(2):210-5. PubMed ID: 25574921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with reduced antituberculous serum drug concentrations in patients with HIV-TB coinfection.
    Ahmed R; Cooper R; Foisy M; Der E; Kunimoto D
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(5):273-6. PubMed ID: 22875581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
    Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
    Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
    Kumar AK; Chandrasekaran V; Kannan T; Murali AL; Lavanya J; Sudha V; Swaminathan S; Ramachandran G
    Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002.
    LoBue PA; Moser KS
    Int J Tuberc Lung Dis; 2005 May; 9(5):501-6. PubMed ID: 15875920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
    Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels.
    Um SW; Lee SW; Kwon SY; Yoon HI; Park KU; Song J; Lee CT; Lee JH
    Int J Tuberc Lung Dis; 2007 Sep; 11(9):972-8. PubMed ID: 17705974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
    Hemanth Kumar AK; Kannan T; Chandrasekaran V; Sudha V; Vijayakumar A; Ramesh K; Lavanya J; Swaminathan S; Ramachandran G
    Int J Tuberc Lung Dis; 2016 Sep; 20(9):1236-41. PubMed ID: 27510252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India.
    Ramachandran G; Agibothu Kupparam HK; Vedhachalam C; Thiruvengadam K; Rajagandhi V; Dusthackeer A; Karunaianantham R; Jayapal L; Swaminathan S
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: A preliminary study.
    Ramachandran G; Hemanth Kumar AK; Kannan T; Thangakunam B; Shankar D; Christopher DJ
    Indian J Med Res; 2023; 157(2&3):211-215. PubMed ID: 36861539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand.
    Maze MJ; Paynter J; Chiu W; Hu R; Nisbet M; Lewis C
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):955-60. PubMed ID: 27287650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
    Park JS; Lee JY; Lee YJ; Kim SJ; Cho YJ; Yoon HI; Lee CT; Song J; Lee JH
    Antimicrob Agents Chemother; 2016 Jan; 60(1):92-8. PubMed ID: 26459901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoniazid and rifampicin concentrations in children with tuberculosis with either a daily or intermittent regimen: implications for the revised RNTCP 2012 doses in India.
    Ranjalkar J; Mathew SK; Verghese VP; Bose A; Rose W; Gupta D; Fleming DH; Mathew BS
    Int J Antimicrob Agents; 2018 May; 51(5):663-669. PubMed ID: 29241821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of Pulmonary Tuberculosis and Detection of Resistance to Rifampin and Isoniazid through Direct Molecular Methods in Stool Samples.
    Yousef SA; AbdelRahim KA; Ahmed AO; Almaary KS; Mohamed AM
    Ann Clin Lab Sci; 2016 Dec; 46(6):616-621. PubMed ID: 27993874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
    Rockwood N; Pasipanodya JG; Denti P; Sirgel F; Lesosky M; Gumbo T; Meintjes G; McIlleron H; Wilkinson RJ
    Clin Infect Dis; 2017 May; 64(10):1350-1359. PubMed ID: 28205671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
    Ramachandran G; Kumar AK; Bhavani PK; Kannan T; Kumar SR; Gangadevi NP; Banurekha VV; Sekar L; Ravichandran N; Mathevan G; Sanjeeva GN; Dayal R; Swaminathan S
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1162-7. PubMed ID: 25487804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
    Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
    Ramachandran G; Kumar AK; Kannan T; Bhavani PK; Kumar SR; Gangadevi NP; Banurekha VV; Sudha V; Venkatesh S; Ravichandran N; Kalpana S; Mathevan G; Sanjeeva GN; Agarwal D; Swaminathan S
    Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.